What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target. The ...

Illumina's divestiture of GRAIL boosts financials, while strong gross margins and DNA sequencing growth drive potential. See ...

In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a ...

The global clinical next-generation sequencing (NGS) market, valued at USD 6.2 billion in 2024, is expected to reach USD 15.2 billion by 2032 with a ...

Illumina’s first quarter results reflected ongoing challenges in the global genomics market, as the company’s performance fell short of market expectations, prompting a negative reaction from ...

Investing.com -- Illumina (NASDAQ: ILMN) stock declined 3.8% Wednesday after Citi downgraded the genomic sequencing company to Sell from Neutral, citing concerns about its second-half outlook.

Illumina inked a deal with Standard BioTools to acquire SomaLogic for $350 million in cash. The maker of gene-sequencing equipment and services said Monday that the deal includes an additional ...

Illumina said the acquisition will bolster its multiomics strategy to diversify beyond DNA sequencing and builds on a yearslong collaboration with the company, while Standard BioTools said the ...

Brown Cancer Center recently became the first facility in the United States of America to offer its patients access to an FDA ...

Illumina expects to close the transaction in the first half of 2026. Price Action: LAB stock is up 33.8% at $1.41, and ILMN stock is up 0.09% at $90.57 at last check Monday. Loading ...

Romanian private healthcare provider MedLife said it will launch in October the country’s first large-scale genetic testing ...